The Business Magazine - B2B Business News - Site Logo
The Business Magazine - B2B Business News - Site Logo
The Business Magazine May 2024
Read now
PICK YOUR EDITION

Oxford Biodynamics' Prostate Screening EpiSwitch blood test much more accurate than widely available test

The Business Magazine article image for: Oxford Biodynamics' Prostate Screening EpiSwitch blood test much more accurate than widely available test
7 February 2023
Share

A widely available prostate-specific antigen (PSA) test which is considered inaccurate by the NHS, could be replaced by one being developed by Oxford Biodynamics, which is proving much more accurate.

A positive result from a standard PSA test is unreliable and often suggests prostate cancer is present when no cancer exists. The inaccuracy of current screening protocols leads to many men getting unnecessary referrals for expensive MRI scans and highly invasive, medieval biopsies. Only about a quarter of people who have a prostate biopsy due to an elevated PSA level are found to have prostate cancer.

Oxford BioDynamics, the biotechnology company developing precision medicine tests based on the EpiSwitch 3D genomics platform, has now published compelling results involving OBD's technology in the multi-disciplinary PROSTAGRAM study using blood to detect prostate cancer in an at risk population. 

The peer-reviewed work, published in the high-impact journal, Cancers, was a collaboration between Oxford Biodynamics, Imperial College London, University of East Anglia, and Imperial College National Health Service (NHS) Trust under the direction of the UK's leading prostate cancer experts.

In the PROSTAGRAM screening pilot study, blood from 147 men enrolled in the study and patients from Imperial College NHS Trust were tested using the standard prostate-specific antigen (PSA) test and an EpiSwitch prostate cancer classifier, developed by Oxford Biodynamics. The resultant Prostate Screening EpiSwitch® (PSE) blood test, which combines the PSA component and the EpiSwitch classifier, demonstrated an accuracy of 94 per cent. 

As a rapid and minimally invasive test, the highly accurate PSE blood test has unprecedented potential as a screening diagnostic that can minimise unnecessary referrals to expensive and invasive procedures.

Principal investigator Mathias Winkler, M.D., F.R.C.S., Consultant Urologist and Surgeon, Charing Cross Hospital and Imperial College London, said: "The EpiSwitch PSE results from this study have significant clinical relevance. We are looking forward to working with OBD to complete all the follow-up steps introducing it to clinical practice, bringing this valuable EpiSwitch® tool into the hands of clinicians." 

Dr Jon Burrows, OBD's Chief Executive Officer, added: "OBD's EpiSwitch 3D genomics platform has once again demonstrated the ability to provide a clinically important diagnostic solution to the global medical community; this time as a highly relevant screening test for prostate cancer. 

"There is a clear need in everyday clinical practice for a highly accurate (94%) blood test that can screen men for prostate cancer and accurately identify those at risk, while sparing those who up to now would be subject to unnecessary, expensive and invasive procedures. This is another example of how OBD's product portfolio can contribute to reducing the total cost of care for global health."


Nicky Godding is editor of The Business Magazine. Before her journalism career, she worked mainly in public relations moving into writing when she was invited to launch Retail Watch, a publication covering retail and real estate across Europe.

After some years of constant travelling, she tucked away her passport and concentrated on business writing, co-founding a successful regional business magazine. She has interviewed some of the UK’s most successful entrepreneurs who have built multi-million-pound businesses and reported on many science and technology firsts.

She reports on the region’s thriving business economy from start-ups, family businesses and multi-million-pound corporations, to the professionals that support their growth and the institutions that educate the next generation of business leaders.

Related topics

Latest deal ticket

All deals
Entaco Ltd (Worcestershire)
has completed an MBO with support from
Traditum (Yorkshire)
May 2024
UNDISCLOSED
Who's behind the deal?

Events

All events
06
Jun

South Coast Property Awards 2024

Hilton Southampton
Utilita Bowl
More info
12
Jun

Leadership Roundtable: Developing strategies for financial returns over the next decade

Herrington Carmichael, Farnborough Aerospace Centre, GU14 6XR

More info
09
Jul

Leadership Roundtable: Opportunities and challenges in the Care Sector

Herrington Carmichael
Farnborough Aerospace Centre, GU14 6XR
More info
18
Jul

Thames Valley Tech & Innovation Awards 2024

Reading FC Conference & Events
Select Car Leasing Stadium, Reading
More info
23
Jul

Leadership Roundtable: Search Fund Exits & Acquisitions

Shawbrook Bank
9 Appold Street, London EC2A 2AP
More info
26
Sep

Thames Valley Property Awards 2024

Ascot Pavilion
Ascot Racecourse
More info
03
Oct

South Coast Tech & Innovation Awards 2024

Hilton Southampton
Utilita Bowl
More info
07
Nov

Thames Valley Deals Awards 2024

Reading FC Conference & Events
Select Car Leasing Stadium, Reading
More info
21
Nov

Hampshire Business Awards 2024

Farnborough International
Exhibition & Conference Centre
More info

Related news


Group Titles

Dorset BIZ NewsHampshire BIZ News
cross